NKCFO LLC’s DexCom DXCM Stock Holding History

NKCFO LLC’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-790	Closed	-$69K	–	112
2025 Q2	$69K	Buy	+790	New	+$61.9K	0.03%	87
2022 Q1	–	Sell	-740	Closed	-$99K	–	128
2021 Q4	$99K	Buy	+740	New	+$106K	0.03%	84

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NKCFO LLC's DXCM Position: Q3 2025 in Review

NKCFO LLC sold out of DexCom (DXCM) in Q3 2025, closing a stake of 790 shares — an estimated $69K sold.

NKCFO LLC first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $99K in Q4 2021. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

NKCFO LLC reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
NKCFO LLC sold 790 DexCom shares in Q3 2025, an estimated $69K.
NKCFO LLC first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
NKCFO LLC's DexCom position peaked at $99K in Q4 2021.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on NKCFO LLC's 13F filing for Q3 2025, filed 10 Nov 2025.